Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TIGIT

TIGIT

Brief Information

Name:T cell immunoglobulin and ITIM domains
Target Synonym:V-Set And Immunoglobulin Domain Containing 9,Washington University Cell Adhesion Molecule,V-Set And Transmembrane Domain Containing 3,WUCAM,DKFZp667A205,FLJ39873,V-set and immunoglobulin domain-containing protein 9,TIGIT,VSIG9,T Cell Immunoreceptor With Ig And ITIM Domains,V-Set And Transmembrane Domain-Containing Protein 3,VSIG9, VSTM3,VSTM3,T-Cell Immunoreceptor With Ig And ITIM Domains
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:38
Lastest Research Phase:Phase 3 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
TIGIT&PVRIG BsAb - 01 PCC Solid Tumor Solid tumor

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TIT-HP2H3 Human PE-Labeled Human TIGIT Protein, His TagStar Staining
TIT-HP2H3-structure
TIT-C82E3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, His,Avitag™ (MALS verified)
TIT-C82E3-sds
TIT-M82F3 Mouse Biotinylated Mouse TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-M82F3-structure
TIT-M82F3-sds
TIT-C82F3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-C82F3-structure
TIT-C82F3-sds
TIT-M82E9 Mouse Biotinylated Mouse TIGIT Protein, His,Avitag™, active dimer (MALS verified)
TIT-M82E9-sds
TIT-H52H5 Human Human TIGIT Protein, His Tag, active dimer (MALS verified)
TIT-H52H5-sds
TIT-H82E6 Human Biotinylated Human TIGIT Protein, His,Avitag™, active dimer (recommended for biopanning) (MALS verified)
TIT-H82E6-sds
TIT-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified)
TIT-C5253-structure
TIT-C5253-sds
TIT-M5253 Mouse Mouse TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified)
TIT-M5253-structure
TIT-M5253-sds
TIT-H82F3 Human Biotinylated Human TIGIT Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
TIT-H82F3-structure
TIT-H82F3-sds
TIT-C52H7 Canine Canine TIGIT Protein, His Tag (MALS verified)
TIT-C52H7-structure
TIT-C52H7-sds
TIT-H5253 Human Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
TIT-H5253-structure
TIT-H5253-sds
TIT-R5259 Rabbit Rabbit TIGIT Protein, Fc Tag (MALS verified)
TIT-R5259-structure
TIT-R5259-sds
TIT-R5258 Rat Rat TIGIT Protein, Fc Tag
TIT-R5258-structure
TIT-R5258-sds
TIT-C5254 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, Fc Tag (MALS verified)
TIT-C5254-structure
TIT-C5254-sds
TIT-C5223 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, His Tag (HPLC verified)
TIT-C5223-structure
TIT-C5223-sds
TIT-C5223-hplc
TIT-H82F1 Human Biotinylated Human TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-H82F1-structure
TIT-H82F1-sds
TIT-M52E6 Mouse Mouse TIGIT Protein, His Tag (MALS verified)
TIT-M52E6-structure
TIT-M52E6-sds
TIT-M5257 Mouse Mouse TIGIT Protein, Fc Tag (MALS verified)
TIT-M5257-structure
TIT-M5257-sds
TIT-H5254 Human Human TIGIT Protein, Fc Tag (MALS verified)
TIT-H5254-structure
TIT-H5254-sds
ACRO Quality

Part of Bioactivity data

TIT-H5253-Cell-based assay
TIGIT FACS

FACS assay shows that Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).

Protocol
TIT-H82F1-Cell-based assay
TIGIT FACS

FACS assay shows Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT is 0.03 μg/mL (Routinely tested).

Protocol
TIT-H52H5-SPR
TIGIT SPR

Anti-hTIGIT antibody captured on CM5 chip via Anti-mouse antibodies surface can bind Human TIGIT, His Tag (Cat. No. TIT-H52H5) with an affinity constant of 1.28 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
TIT-C52H7-BLI
TIGIT BLI

Loaded Human CD155, Fc Tag (Cat. No. CD5-H5251) on Protein A Biosensor, can bind Canine TIGIT, His Tag (Cat. No. TIT-C52H7) with an affinity constant of 5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Customer Reviews

Synonym Name

TIGIT,VSIG9,VSTM3

Background

TIGIT has been shown to be over expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TIL). Blockade of TIGIT led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells, which now make it be considered as an immune checkpoint. Recently, studies have shown anti-TIGIT antibody is promising to become a cancer immunotherapy. Our ELISA kit is designed to help the discovery of anti-TIGIT therapeutic antibody.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vibostolimab MK-7684 Phase 3 Clinical Merck Sharp & Dohme Corp Solid tumours; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Domvanalimab AB-154 Phase 3 Clinical Arcus Biosciences Inc Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lung Neoplasms; Esophageal adenocarcinoma; Cholangiocarcinoma; Biliary Tract Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Liver Neoplasms Details
Tiragolumab RO-7092284; MTIG-7192A; RG-6058 Phase 3 Clinical F. Hoffmann-La Roche Ltd Carcinoma, Squamous Cell; Multiple Myeloma; Chordoma; Lymphoma, Follicular; Breast Neoplasms; Sarcoma; Esophageal Squamous Cell Carcinoma; Lymphoma, Non-Hodgkin; Mouth Neoplasms; Carcinoma, Medullary; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Hemangioendothelioma, Epithelioid; Neoplasm Metastasis; Stomach Neoplasms; Liver Neoplasms; Teratoma; Lymphoma, B-Cell; Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Solid tumours; Esophageal Neoplasms; Rhabdoid Tumor; Carcinoma, Transitional Cell; Glioblastoma; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms Details
Pembrolizumab/Vibostolimab MK-7684A Phase 3 Clinical Merck & Co Inc Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Gallbladder Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms Details
Rilvegostomig AZD-2936 Phase 3 Clinical Astrazeneca Plc Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ociperlimab BGB-A1217 Phase 3 Clinical Beigene Ltd Solid tumours; Biliary Tract Neoplasms; Lymphoma, B-Cell; Esophageal Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
Etigilimab OMP-313M32 Phase 2 Clinical Oncomed Pharmaceuticals Inc Ovarian Neoplasms; Solid tumours; Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Neoplasm Metastasis Details
Renvistobart BMS-986207 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ZG-005 ZG-005 Phase 2 Clinical Gensun Biopharma Inc Solid tumours; Neoplasms; Carcinoma, Neuroendocrine; Uterine Cervical Neoplasms Details
HB-0036 HB-0036 Phase 2 Clinical Solid tumours; Carcinoma, Non-Small-Cell Lung Details
AGEN-1777 AGEN-1777; BMS-986442 Phase 2 Clinical Agenus Inc Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PM-1022 PM-1022 Phase 2 Clinical Biotheus Inc Neoplasms Details
Lancastotug AK-127 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms; Carcinoma, Hepatocellular Details
Belrestotug EOS-448; EOS-884448; GSK-4428859; GSK-4428859A Phase 2 Clinical Iteos Head and Neck Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Multiple Myeloma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
HLX-301 HLX-301 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
HLX-53 HLX-53; HLX53 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular; Neoplasm Metastasis Details
HL-301 HL-301 Phase 2 Clinical Hanlim Pharm Co Ltd Radiation Pneumonitis; Small Cell Lung Carcinoma; Lung Neoplasms Details
JS-006 JS-006; TAB-006; CHS-006 Phase 2 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Dargistotug M-6223; M6223 Phase 2 Clinical Emd Serono Research & Development Institute Inc Solid tumours; Carcinoma, Transitional Cell; Neoplasm Metastasis Details
DW-2008 DW-2008; DW-2008S Phase 1 Clinical Dong Wha Pharm Co Ltd Coronavirus Disease 2019 (COVID-19); Rhinitis, Allergic; Asthma Details
Tamgiblimab IBI-939 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms; Lung Neoplasms Details
COM-902 COM-902 Phase 1 Clinical Compugen Ltd Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Colorectal Neoplasms; Lung Neoplasms Details
AK-130 AK-130 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Neoplasms; Carcinoma, Hepatocellular Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma) LP-010 Phase 1 Clinical Solid tumours Details
ASP-8374 ASP-8374; PTZ-201 Phase 1 Clinical Potenza Therapeutics, Astellas Pharma Inc Solid tumours; Glioblastoma Details
ZGGS-15 ZGGS15; ZGGS-15 Phase 1 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details
AUR-106 AUR-106 Phase 1 Clinical Aurigene Discovery Technologies Ltd Kidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BC008-1A BC008-1A Phase 1 Clinical Sichuan Luzhou Buchang Biopharmaceutical Co Ltd Solid tumours Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
PM-1021 PM1021 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms Details
SHS-006(Nanjing Sanhome Pharmaceutical) SHS-006; SH-006; SH006 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours Details
HB0030 HB-0030 Phase 1 Clinical Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours Details
BAT-6005 BAT-6005 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
Ralzapastotug AB-308 Phase 1 Clinical Arcus Biosciences Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap